Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT002 in healthy participants
NCT05491421Phase 1Completed
- Sponsor
- QL Biopharm
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ZT002 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 71 days and Serious Adverse Events at 71 days. Started Sep 2022; status: completed.
02
Drugs
zovaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05491421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491421.